Supplementary Figure 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

作者：Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica Lee, Joao V. Alessi, Adriana Barrichello, Victor R. Vaz, Giuseppe Lamberti, Alessandro Di Federico, Malini Gandhi, Dimitris Gazgalis, William W. Feng, Jie Jiang, Simon Baldacci, Marie-Anaïs Locquet, Felix H. Gottlieb, Monica F. Chen, Elinton Lee, Danielle Haradon, Anna Smokovich, Emma Voligny, Tom Nguyen, Vikas K. Goel, Zachary Zimmerman, Sumandeep Atwal, Xinan Wang, Magda Bahcall, Rebecca S. Heist, Sumaiya Iqbal, Nishant Gandhi, Andrew Elliott, Ari M. Vanderwalde, C. Patrick, Balázs Halmos, Stephen V. Liu, Jianwei Che, Alexa B. Schrock, Alexander Drilon, Pasi A. Jänne, Mark M. Awad · 年份：2026 · DOI：10.1158/2159-8290.32698161 · 研究领域：Lung Cancer Treatments and Mutations、Fibroblast Growth Factor Research、Liver physiology and pathology

<p>MET TKD mutations in NSCLC in cohort #1 and #2. (A) Flowchart of the NSCLC subgroup in cohort #1 (123 MET TKD mutations in 120 unique patients); (B) Prevalence of MET TKD mutations in NSCLC cases according to each dataset in cohort #1; (C) Lollipop plot of the oncogenic / likely oncogenic MET TKD mutations detected in NSCLC cases of cohort #1 (47 oncogenic / likely oncogenic MET TKD mutations in 44 unique patients); (D) Flowchart of the NSCLC subgroup in cohort #2 (590 MET TKD mutations in 586 unique patients); (E) Prevalence of MET TKD mutations in NSCLC cases according to cohort #2 (590 MET TKD mutations in 586 unique patients); (F) Lollipop plot of the oncogenic / likely oncogenic MET TKD mutations detected in NSCLC cases of cohort #2 (129 oncogenic / likely oncogenic MET TKD mutations in 129 unique patients).</p>